Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...